InspireMD (NYSE:NSPR) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Friday morning. The firm issued a sell rating on the stock.

Separately, Piper Sandler reaffirmed an “overweight” rating and set a $4.50 target price on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Stock Performance

Shares of NYSE NSPR opened at $2.45 on Friday. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.77. The company has a market cap of $61.08 million, a price-to-earnings ratio of -3.22 and a beta of 0.91. The business’s 50 day moving average price is $2.69 and its 200-day moving average price is $2.56.

InspireMD (NYSE:NSPR) last released its earnings results on Tuesday, August 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The business had revenue of $1.74 million for the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative return on equity of 62.02% and a negative net margin of 388.67%. During the same quarter last year, the business posted ($0.24) earnings per share. Sell-side analysts predict that InspireMD will post -0.82 earnings per share for the current year.

Hedge Funds Weigh In On InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Affiance Financial LLC bought a new position in shares of InspireMD, Inc. (NYSE:NSPR) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned approximately 0.74% of InspireMD at the end of the most recent reporting period. Institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.